Text Size

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

This study has been completed.
Sponsor:
Collaborator:
Instituto Nacional de Referencia Epidemiológica (INdRE)
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00600236
First received: June 30, 2006
Last updated: January 23, 2008
Last verified: January 2008
History of Changes
  Purpose

One of the first causes of irreversible blindness in mexican population is diabetic retinopathy which is clearly diferent between patients the time of evolution and development of retinopathy and complications. The aim of this study is to explore the inmunogenetic profile and the influence of HLA in this variations of the sickness to predict the severity of diabetic complications.


Condition Intervention Phase
Diabetes Mellitus Type 2
Proliferative Diabetic Retinopathy
 Procedure: blood sample
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Prevention
Official Title: HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Asociación para Evitar la Ceguera en México:

Estimated Enrollment: 300
Study Start Date: September 2004
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
  • Diabetes mellitus type 2 with 10 years of diagnosis and proliferative retinopathy

Exclusion Criteria:

  • Systemic hipertension
  • Cardic disease
  • Lupus
  • Any kind of artritis
  • Allergies
  • Optic Neuritis
  • VKH
  • Cancer
  • Inmunological diseases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00600236

Locations
Mexico
Asociación para Evitar la Ceguera en México, Hospital "Luis Sanchez Bulnes"
Mexico City, Mexico DF, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Instituto Nacional de Referencia Epidemiológica (INdRE)
Investigators
Principal Investigator: Hugo Quiroz-Mercado, MD Asociación para Evitar la Ceguera en México, Hospital "Luis Sánchez Bulnes"
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00600236     History of Changes
Other Study ID Numbers: APEC-0018
Study First Received: June 30, 2006
Last Updated: January 23, 2008
Health Authority: Mexico: Secretaria de Salud

Keywords provided by Asociación para Evitar la Ceguera en México:
Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
Diabetes mellitus type 2 with 10 years of diagnosis and proliferative diabetic retinopathy

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetic Retinopathy
Retinal Diseases
Glucose Metabolism Disorders
Metabolic Diseases
 Endocrine System Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications

ClinicalTrials.gov processed this record on May 22, 2013